Market Research Reports

Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, Modern and Human Insulin) - Industry Analysis, Size, Share, Growth, Trends and Forecast (Value and Volume), 2013 - 2019

99pages
Published Date: 2014-06-19
 

Description



Diabetes, growing at an exponential rate worldwide, has become a serious health concern. The disease has emerged as a major cause of death of people between 20 years and 80 years of age. According to the American Diabetes Association, around 5% of the U.S. population has type 1 diabetes (approximately 1 million) and 95% of the population suffers from type 2 diabetes. Insulin plays an integral role in absorption of glucose from blood in case of type 1 and type 2 diabetes. Eli Lilly was the first company who made the human insulin commercially available in early 1980s. Since then insulin industry has been witnessing continuous advancements and innovations with various insulin derivatives available in the market. This report on insulin market analyzes the current as well as future prospects of the global and China market for insulin. This research is designed to estimate and analyze the demand and performance of insulin in the global market and also with special focus on the insulin market in China. This report on insulin provides in-depth analysis of the insulin market by revenue, volume, price trends and trend analysis by segments and demand in the global and China market.

The global and China insulin market is segmented based on mode of action into fast-acting insulin, short-acting insulin, long-acting insulin, intermediate-acting insulin and premixed insulin. Furthermore, the insulin market is also classified on the basis of source namely, human insulin and modern insulin. The market for these segments is extensively analyzed based on leading drug launches, expiry, efficacy, sales revenue and geographic presence. The market size, volume and forecast in terms of USD million for each type of insulin has been provided for the period 2011 to 2019, considering 2012 as the base year. This report on global and China insulin market also provides % compounded annual growth rate (CAGR) for each market segment for the forecast period 2013 to 2019, considering 2012 as the base year. 

The research study also incorporates a detailed qualitative analysis of the factors responsible for driving and restraining growth of the global insulin market. Future opportunities have also been provided in the market overview section. This section of the report also deals with market attractiveness analysis and Porter’s five forces analysis for the global insulin market. Further, value chain analysis (VCA) for the insulin market is also provided that highlights manufacturing, processing and distribution process of this industry. Market attractiveness is estimated for different class of insulin derivates using PESTEL analysis approach. Thus, entire section of the market overview plays an important role in understanding the insulin market on global level and China market.

This report on global and China insulin market includes a section on competitive landscape, which provides market share analysis of leading players in the insulin market, in terms of percentage share in the year 2012. Moreover, the report also provides a separate market share analysis of the key players dominating the insulin market in China. A list of recommendations has also been provided for new entrants as well as existing market players to help establish a strong presence in the market and increase their market share. The report comprises pipeline analysis of the market, which includes sales forecast for various drugs currently under phase III clinical trials and are expected to be launched during the forecast period.

The report concludes with profiles of major players in the insulin market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include Novo Nordisk, Sanofi, Eli Lilly and Company and Shanghai Fosun Pharmaceuticals.

The global and China insulin market is segmented as follows:
  • Global and China Insulin Market, by Mode of Action
    • Long-Acting
    • Rapid-Acting
    • Short-Acting
    • Intermediate-Acting
    • Premixed
  • Global and China Insulin Market, by Source
    • Modern
    • Human

Table of Contents



Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Sources
               1.3.1.1 Secondary Research
               1.3.1.2 Primary Research
      1.3.2 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Insulin Market (2012 & 2019)
2.2 Market Snapshot: China Insulin Market (2012 & 2019)

Chapter 3 Market Overview
3.1 Overview
3.2 Market Drivers
      3.2.1 Global rise in diabetic population
      3.2.2 No strict regulations on price capping
      3.2.3 High entry barriers for biosimilar manufacturers
3.3 Market Restraints
      3.3.1 Growing acceptance of SGLT2 and GLP-1 agents among type 2 diabetes patients will delay the shift to insulin therapy
      3.3.2 High cost of products restrains the uptake of insulin in emerging markets
3.4 Market Opportunities
      3.4.1 Development of combination products
      3.4.2 Strong Pipeline
3.5 Value Chain: Global Insulin Market
3.6 Porter’s Five Force Analysis of the Global Insulin Market
      3.6.1 Bargaining power of suppliers
      3.6.2 Bargaining power of buyers
      3.6.3 Threat of substitutes
      3.6.4 Threat of new entrants
      3.6.5 Competitive rivalry
3.7 Market Attractiveness Analysis: Global Insulin Market, by Mode of Action

Chapter 4 Global Insulin Market, by Mode of Action
4.1 Overview
      4.1.1 Characteristics of type of Insulin
      4.1.2 Global Insulin Market Revenue, by Mode of Action, 2011 – 2019 (USD Million)
      4.1.3 Global Insulin Market Volume, by Mode of Action, 2011 – 2019 (tMU)
      4.1.4 Comparative Analysis: Global Insulin Market Revenue, by Mode of Action, 2012 & 2019 (Value %)
4.2 Short-Acting Insulin
      4.2.1 Global Short-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
      4.2.2 Global Short-Acting Insulin Market Volume, 2011 – 2019 (tMU)
4.3 Rapid-Acting Insulin
      4.3.1 Global Rapid-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
      4.3.2 Global Rapid-Acting Insulin Market Volume, 2011 – 2019 (tMU)
      4.3.3 Pipeline Analysis
               4.3.3.1 Afrezza
                          4.3.3.1.1 Global Afrezza Market Revenue, 2015 – 2019 (USD Million)
               4.3.3.2 NN1218 (FIAsp)
                          4.3.3.2.1 Global NN1218 Market, 2016 – 2019 (USD Million)
4.4 Long-Acting Insulin
      4.4.1 Global Long-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
      4.4.2 Global Long-Acting Insulin Market Volume, 2011 – 2019 (tMU)
      4.4.3 Pipeline Analysis
               4.4.3.1 LY2605541(Novel Basal Insulin Analog)
                          4.4.3.1.1 Global LY2605541 Market Revenue, 2015 – 2019 (USD Million)
               4.4.3.2 LY2963016 (Long acting basal insulin)
                          4.4.3.2.1 Global LY2963016 Market Revenue, 2014 – 2019 (USD Million)
               4.4.3.3 MK-1293 (Sustained release insulin analog)
                          4.4.3.3.1 Global MK-1293 Market Revenue, 2016 – 2019 (USD Million)
               4.4.3.4 U-300 (Toujeo)
                          4.4.3.4.1 Global U-300 Market Revenue, 2015 – 2019 (USD Million)
               4.4.3.5 IDegLira (Xultophy)
                          4.4.3.5.1 Global IDegLira Market Revenue, 2014 – 2019 (USD Million)
4.5 Intermediate-Acting Insulin
      4.5.1 Global Intermediate-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
      4.5.2 Global Intermediate-Acting Insulin Market Volume, 2011 – 2019 (tMU)
4.6 Premixed Insulin
      4.6.1 Global Premixed Insulin Market Revenue, 2011 – 2019 (USD Million)
      4.6.2 Global Premixed Insulin Market Volume, 2011 – 2019 (tMU)

Chapter 5 China Insulin Market, by Mode of Action
5.1 Overview
5.2 Breakdown of insulin-dependent population in China (2009)
      5.2.1 China Insulin Market Revenue, by Mode of Action, 2011 – 2019 (USD Million)
      5.2.2 China Insulin Market Volume, by Mode of Action, 2011 – 2019 (tMU)
5.3 Short-Acting Insulin
      5.3.1 China Short-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
      5.3.2 China Short-Acting Insulin Market Volume, 2011 – 2019 (tMU)
5.4 Rapid-Acting Insulin
      5.4.1 China Rapid-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
      5.4.2 China Rapid-Acting Insulin Market Volume, 2011 – 2019 (tMU)
5.5 Long-Acting Insulin
      5.5.1 China Long-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
      5.5.2 China Long-Acting Insulin Market Volume, 2011 – 2019 (tMU)
5.6 Intermediate-Acting Insulin
      5.6.1 China Intermediate-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
      5.6.2 China Intermediate -Acting Insulin Market Volume, 2011 – 2019 (tMU)
5.7 Premixed Insulin
      5.7.1 China Premixed Insulin Market Revenue, 2011 – 2019 (USD Million)
      5.7.2 China Premixed Insulin Market Volume, 2011 – 2019 (tMU)

Chapter 6 Global Insulin Market, by Source
6.1 Overview
      6.1.1 Global Insulin Market Revenue, by Source, 2011 – 2019 (USD Million)
      6.1.2 Global Insulin Market Volume, by Source, 2011 – 2019 (tMU)
6.2 Human Insulin
      6.2.1 Global Human Insulin Market Revenue, 2011 – 2019 (USD Million)
      6.2.2 Global Human Insulin Market Volume, 2011 – 2019 (tMU)
6.3 Modern Insulin
      6.3.1 Global Modern Insulin Market Revenue, 2011 – 2019 (USD Million)
      6.3.2 Global Modern Insulin Market Volume, 2011 – 2019 (tMU)

Chapter 7 China Insulin Market, by Source
7.1 Overview
      7.1.1 China Insulin Market Revenue, by Source, 2011 – 2019 (USD Million)
      7.1.2 China Insulin Market Volume, by Source, 2011 – 2019 (tMU)
7.2 Human Insulin
      7.2.1 China Human Insulin Market Revenue, 2011 – 2019 (USD Million)
      7.2.2 China Human Insulin Market Volume, 2011 – 2019 (tMU)
7.3 Modern Insulin
      7.3.1 China Modern Insulin Market Revenue, 2011 – 2019 (USD Million)
      7.3.2 China Modern Insulin Market Volume, 2011 – 2019 (tMU)

Chapter 8 Competitive Landscape
8.1 Market Share Analysis: Global Insulin Market, 2012 (%)
      8.1.1 Global Insulin Market Share Analysis, by Key Players, 2012 (%)
8.2 Market Share Analysis: China Insulin Market, 2012 (%)
      8.2.1 China Insulin Market Share Analysis, by Key Players, 2012 (%)

Chapter 9 Recommendations
9.1 Development of formulations that can be administered by different routes
9.2 Development of combination formulations
9.3 Overcoming technical incompatibilities
9.4 Focus on emerging markets

Chapter 10 Company Profiles
10.1 Eli Lilly and Company
      10.1.1 Company Overview
      10.1.2 Financial Overview
      10.1.3 Product Portfolio
      10.1.4 Business Strategies
      10.1.5 Recent Developments
10.2 Novo Nordisk A/S
      10.2.1 Company Overview
      10.2.2 Financial Overview
      10.2.3 Product Portfolio
      10.2.4 Business Strategies
      10.2.5 Recent Developments
10.3 Sanofi
      10.3.1 Company Overview
      10.3.2 Financial Overview
      10.3.3 Product Portfolio
      10.3.4 Business Strategies
      10.3.5 Recent Developments
10.4 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
      10.4.1 Company Overview
      10.4.2 Financial Overview
      10.4.3 Business Overview
      10.4.4 Recent Developments

List of Figures

FIG. 1 Insulin: Market Segmentation
FIG. 2 Global Insulin Market Revenue, by Mode of Action, 2012 (USD Million)
FIG. 3 China Insulin Market Revenue, by Mode of Action, 2012 (USD Million)
FIG. 4 Value Chain: Global Insulin Market
FIG. 5 Porter’s Five Forces Analysis: Global Insulin Market
FIG. 6 Market Attractiveness Analysis: Global Insulin Market, by Mode of Action
FIG. 7 Comparative Analysis: Global Insulin Market Revenue, by Mode of Action 2012 & 2019 (Value %)
FIG. 8 Global Short-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 9 Global Short-Acting Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 10 Global Rapid-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 11 Global Rapid-Acting Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 12 Global Afrezza Market Revenue, 2015 – 2019 (USD Million)
FIG. 13 Global NN1218 Market Revenue, 2016 – 2019 (USD Million)
FIG. 14 Global Long-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 15 Global Long-Acting Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 16 Global LY2605541 Market Revenue, 2015 – 2019 (USD Million)
FIG. 17 Global LY2963016 Market Revenue, 2014 – 2019 (USD Million)
FIG. 18 Global MK-1293 Market Revenue , 2016 – 2019 (USD Million)
FIG. 19 Global U-300 Market Revenue, 2015 – 2019 (USD Million)
FIG. 20 Global IDegLira Market Revenue, 2014– 2019 (USD Million)
FIG. 21 Global Intermediate-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 22 Global Intermediate-Acting Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 23 Global Premixed Market Revenue, 2011 – 2019 (USD Million)
FIG. 24 Global Premixed Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 25 Breakdown of insulin-dependent population in China (2009)
FIG. 26 China Short-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 27 China Short-Acting Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 28 China Rapid-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 29 China Rapid-Acting Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 30 China Long-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 31 China Long-Acting Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 32 China Intermediate-Acting Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 33 China Intermediate-Acting Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 34 China Premixed Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 35 China Premixed Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 36 Global Human Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 37 Global Human Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 38 Global Modern Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 39 Global Modern Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 40 China Human Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 41 China Human Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 42 China Modern Insulin Market Revenue, 2011 – 2019 (USD Million)
FIG. 43 China Modern Insulin Market Volume, 2011 – 2019 (tMU)
FIG. 44 Global Insulin Market Share Analysis, by Key Players, 2012 (%)
FIG. 45 Global Insulin Market Share Analysis, by Key Players, 2012 (%)
FIG. 46 Eli Lilly and Company: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 47 Novo Nordisk A/S.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 48 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 49 Shanghai Fosun Pharmaceutical Co., Ltd.: Annual Revenue, 2011 – 2013 (USD Million)

List of Tables
 
TABLE 1 Market Snapshot: Global Insulin Market (2012 & 2019)
TABLE 2 Market Snapshot: China Insulin Market (2012 & 2019)
TABLE 3 Global Insulin Market Revenue, by Mode of Action, 2011 – 2019 (USD Million)
TABLE 4 Global Insulin Market Volume, by Mode of Action, 2011 – 2019 (tMU)
TABLE 5 China Insulin Market Revenue, by Mode of Action, 2011 – 2019 (USD Million)
TABLE 6 China Insulin Market Volume, by Mode of Action, 2011 – 2019 (tMU)
TABLE 7 Global Insulin Market Revenue, by Source, 2011 – 2019 (USD Million)
TABLE 8 Global Insulin Market Volume, by Source, 2011 – 2019 (tMU)
TABLE 9 China Insulin Market Revenue, by Source, 2011 – 2019 (USD Million)
TABLE 10 China Insulin Market Volume, by Source, 2011 – 2019 (tMU)

Enquiry Before Buying


Free Market Analysis


Diabetes is a chronic metabolic disorder wherein the body is either unable to produce insulin (glucose digesting hormone) or unable to utilize the produced insulin to metabolize blood glucose. This condition results in increased blood glucose level, which leads to various chronic and life-threatening diseases. Insulin is a hormone secreted by β-cells of pancreas in order to metabolize the blood sugar. The insulin market is a rapidly growing market. Demand for premixed and long-acting insulin derivatives is growing rapidly due to rising incidences of type 1 diabetes. This report focuses on identifying the current scenario as well as the future market potential for insulin globally. Additionally, the insulin market in China is also analyzed and studied thoroughly. The insulin market is segmented based on two important parameters: by mode of action and by source. By mode of action, the market (global and China) is categorized as rapid-acting, short-acting, intermediate-acting, long-acting and premixed insulin derivatives. Furthermore, by source, the market is categorized as human insulin and modern insulin.

Long-acting insulin derivatives is projected to be the fastest growing segment, expanding at a CAGR of 8.7% during the forecast period from 2013 to 2019. According to the World Health Organization (WHO), more than 366 million people worldwide were diagnosed with diabetes in 2011 and an additional 280 million are expected to be diagnosed over the next 20 years. Majority of these patients are likely to be from emerging markets such as China and India. 

Rising demand for long-acting insulin derivatives is attributed to advantages such as reduced number of doses compared to other derivatives. Moreover, strong pipeline, lack of stringent regulations on price capping and high entry barriers for biosimilar manufacturers are other important growth drivers in the market. The market for modern insulin is also expected to increase during the forecast period from 2013 to 2019 due to various factors such as ease-of-administration and higher efficacy.

In China, premixed insulin derivatives accounted for more than 50% of the market in 2012. Large population of type 1 diabetes patients and rising preference for insulin as diabetes treatment (both type 1 and type 2) are some of the factors contributing to the growth of the insulin market in China. Moreover, improving medical infrastructure, changing lifestyle, increased consumption of fast food and changing dietary habits are some of the factors expected to drive the insulin market in China.

The global insulin market is highly consolidated and dominated by few market players such as Eli Lilly and Company, Sanofi, and Novo Nordisk A/S. Moreover, these players account for more than 80% of the total insulin market in China. Domestic players such as Shanghai Fosun Pharmaceutical Co., Ltd. and Tonghua Dongbao hold a small share in the Chinese market.

insulin-market
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research